Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Extension in Psoriasis
NCT02203851Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2014
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of risankizumab in plaque psoriasis (2 arms), sponsored by AbbVie Inc. Primary endpoints: Treatment-Emergent Adverse Events up to 4 years, Drug-related Treatment-Emergent Adverse Events up to 4 years and 2 more. Started Nov 2014; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02203851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203851.